D

DocTrials | Arizona Retina and Vitreous Consultants

Research site

(Unclaimed)

Location

1728 W. Glendale Avenue, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Faricimab

Razuprotafib

Pemafibrate

IONIS-FB-LRx

RG7774

AVD-104

Triamcinolone Acetonide

Abicipar Pegol

AKB-9778

Parent organization

This site is a part of DocTrials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 20 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting

Macular Degeneration

Geographic Atrophy of the Macula

Drug: AVD-104

Drug: Avacincaptad

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling

Neovascular Age-related Macular Degeneration

Device: SUSVIMO PDS Implant

Drug: LUCENTIS (ranibizumab injection)

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Ranibizumab refill exchange

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL